Preclinical Investigation of
Acetamides
/ chemistry
Animals
Fluorouracil
/ pharmacology
Heterocyclic Compounds, 1-Ring
/ chemistry
Humans
Lead
/ pharmacology
Mice
Neuroendocrine Tumors
/ drug therapy
Octreotide
/ chemistry
Radioisotopes
/ chemistry
Radiopharmaceuticals
/ chemistry
Receptors, Peptide
/ chemistry
Somatostatin
/ chemistry
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
25
09
2018
revised:
29
11
2018
accepted:
15
03
2019
pubmed:
31
3
2019
medline:
24
3
2020
entrez:
31
3
2019
Statut:
ppublish
Résumé
Somatostatin analogues have been examined as a treatment for somatostatin receptor overexpressing tumors for years; specifically, octreotate (TATE) and octreotide (TOC). Several versions of these analogues coupled to beta or gamma nuclides are currently used as imaging agents, as treatments with peptide receptor radionuclide therapy (PRRT) for patients with neuroendocrine tumors or are being explored in preclinical and clinical settings. Our study describes the use of
Identifiants
pubmed: 30926632
pii: 1535-7163.MCT-18-1103
doi: 10.1158/1535-7163.MCT-18-1103
pmc: PMC6497546
mid: NIHMS1525261
doi:
Substances chimiques
1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane
0
Acetamides
0
Heterocyclic Compounds, 1-Ring
0
Radioisotopes
0
Radiopharmaceuticals
0
Receptors, Peptide
0
Lead
2P299V784P
Somatostatin
51110-01-1
Octreotide
RWM8CCW8GP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1012-1021Subventions
Organisme : NCI NIH HHS
ID : HHSN261201600015C
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2106-19
pubmed: 25070685
Eur J Nucl Med Mol Imaging. 2006 Jun;33(6):749-50
pubmed: 16568207
J Agric Food Chem. 1998 Feb 16;46(2):490-498
pubmed: 10554268
Food Chem Toxicol. 1995 Mar;33(3):223-31
pubmed: 7896233
J Nucl Med. 2015 Jun;56(6):847-54
pubmed: 25952736
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):897-903
pubmed: 16467104
Gut. 2002 Jan;50(1):52-60
pubmed: 11772967
Appl Radiat Isot. 2013 Jun;76:63-9
pubmed: 22939572
Bioconjug Chem. 2001 Jul-Aug;12(4):554-8
pubmed: 11459460
Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):743-8
pubmed: 18188559
Clin Nucl Med. 2017 Nov;42(11):e457-e466
pubmed: 28872545
Int J Radiat Biol. 2013 Oct;89(10):851-62
pubmed: 23607451
Acta Oncol. 2005;44(7):687-93
pubmed: 16227158
Cancer Biother Radiopharm. 2004 Feb;19(1):35-41
pubmed: 15068609
Cancer Biother Radiopharm. 2009 Oct;24(5):527-33
pubmed: 19877882
Semin Nucl Med. 1995 Jul;25(3):251-61
pubmed: 7570044
Nucl Med Biol. 2007 Feb;34(2):185-93
pubmed: 17307126
J Clin Oncol. 2008 May 1;26(13):2124-30
pubmed: 18445841
Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):302-11
pubmed: 21052661
Theranostics. 2016 Mar 10;6(5):650-65
pubmed: 27022413
J Nucl Med. 2012 May;53(5):749-53
pubmed: 22496587
Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):9-15
pubmed: 12483404
Oncol Rep. 2006 Nov;16(5):1085-91
pubmed: 17016597
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
EJNMMI Res. 2016 Dec;6(1):6
pubmed: 26791386
J Nucl Med. 2005 Sep;46(9):1561-9
pubmed: 16157541
J Nucl Med. 2010 Jul;51(7):1049-58
pubmed: 20554737
Int J Endocr Oncol. 2015;2(2):159-168
pubmed: 26257863
Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):623-32
pubmed: 21170526
Eur J Surg Oncol. 2012 Jan;38(1):64-71
pubmed: 21906907